A total of 260,189 participants (including 2,906 cases) were included in our meta-analysis, which revealed statistically significant associations of increased serum ferritin and transferrin saturation levels with the decreased risk of prostate cancer. The gene discussed is TF; the disease is prostate carcinoma.